Pharmacist Digest

Startup Neuroglee raises $10m for virtual neurology clinics

pharmaphorum

SEPTEMBER 10, 2021

A digital health company focusing on neurodegenerative disorders – Neuroglee Therapeutics – has raised $10 million in first-round funding to roll out a virtual neurology clinics for people with cognitive problems caused by dementia. The post Startup Neuroglee raises $10m for virtual neurology clinics appeared first on.

Mayo Clinic

Mayo Clinic Pharmaceutical Companies Pharmaceutical Companies

The future of clinical research in neurology must be driven by community voices

pharmaphorum

NOVEMBER 17, 2022

In the pursuit of a personalised future for neurological care, collaboration and co-creation should be at the forefront of all research and development. The first step is recognising that within many neurological conditions, the community is diverse. That way, everything we do for patients, we do with patients.

Drug Development

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT

DECEMBER 6, 2023

Abbvie announced Wednesday that it will purchase Cerevel Therapeutics and its pipeline of experimental neurological and psychiatric medications for $8.7 The deal marks the second billion-dollar acquisition by AbbVie in under a week. Continue to STAT+ to read the full story…

STAT+: Biotech launches with $82 million for Parkinson’s cell therapy

STAT

FEBRUARY 29, 2024

Now, a new biotech hopes to do the same for patients with neurological conditions. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Drug Development

STAT+: Taysha Gene Therapies’ plan to tackle rare diseases is crumbling

STAT

SEPTEMBER 29, 2023

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases. Continue to STAT+ to read the full story…

STAT+: After four patients died of gene therapy, Astellas sees possible explanation — and a way forward

STAT

NOVEMBER 15, 2023

In an analysis of its clinical trial , published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. Three died in 2020; the fourth died a year later.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

STAT+: FDA approves first treatment for Rett syndrome, a genetic neurological disease

STAT

MARCH 11, 2023

The Food and Drug Administration on Friday approved the first treatment for Rett syndrome, a genetic disease mostly affecting girls that causes severe neurologic impairments, robbing them of the ability to communicate or control muscle movement. The new drug, called Daybue, is made by Acadia Pharmaceuticals.

Communication

Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say

STAT

MAY 3, 2023

Studies in human brain tissue, neural stem cells, and mice have suggested that this common virus, best known for causing cold sores, might trigger the deadly and devastating neurological disease. Read the rest…

SAEM Clinical Images Series: Intracranial Abnormality

ALiEM - Pharm Pearls

OCTOBER 27, 2023

Copyright Images and cases from the Society of Academic Emergency Medicine (SAEM) Clinical Images Exhibit at the 2023 SAEM Annual Meeting | Copyrighted by SAEM 2023 – all rights reserved. View other cases from this Clinical Image Series on ALiEM. Additional Images Physical Exam Vitals : BP 101/63; HR 76; RR 14; T 36.7°C

BMS Receives EC Approval for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

LifeProNow

MAY 8, 2023

With Breyanzi, people in Europe living with relapsed or refractory DLBCL now have a differentiated CAR T cell therapy option earlier in the treatment paradigm that provides long-term clinical benefit,” said Anne Kerber, senior vice president, head of Cell Therapy Development, Bristol Myers Squibb. months vs. 2.3 NR) with Breyanzi vs. 6.2

Chemotherapy

Chemotherapy Adverse Reactions

STAT+: PTC Therapeutics’s PKU drug succeeds in trial, but bigger hurdles for company are ahead

STAT

MAY 17, 2023

In PKU, patients’ bodies are unable to break down the amino acid phenylalanine, resulting in intellectual disability, memory problems, and other neurological issues. He’d previously said that a 40% to 50% reduction in phenylalanine, or “Phe,” levels would be clinically important.

STAT+: Roche shortens delivery time for multiple sclerosis drug from hours to minutes in trial

STAT

JULY 13, 2023

For people living with multiple sclerosis, slowing or stopping this chronic and debilitating neurological disease often means sitting through hours-long infusion sessions, during which treatments slowly drip into a patient’s bloodstream.

Breaking Down the 2024 PRITE Blueprint

Board Vitals - Pharmacist

NOVEMBER 15, 2023

Clinical Neurosciences (69 Items) Neurodevelopment Neuroanatomy Neurophysiology Genetics B. The BoardVitals Psychiatry Question Bank contains more than 1,450 psychiatry questions, and follows the exam content outline for both the PRITE and the American Board of Psychiatry and Neurology (ABPN) Psychiatry Certification Exam.

AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease

World Pharma News

APRIL 16, 2024

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, on Sunday April 14 presented results from the 18-month Phase Ib clinical trial for AB-1005, an investigational gene therapy for treating patients with Parkinson's disease (PD).(1,2)

Contineum, a startup born from a Roche buyout, files for IPO

BioPharma Dive

MARCH 17, 2024

The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.

Immunity

Immunity Immunization

PharmaKure partners with Malaysian university in a bid to predict neurological diseases

Outsourcing Pharma

DECEMBER 12, 2023

Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimerâs Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.

STAT+: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn

STAT

FEBRUARY 17, 2023

It will once again test his willingness to apply the FDA’s doctrine of “regulatory flexibility” to a medicine with less-than-convincing clinical data.

Encouraging results for Parkinson's Disease drug in Biovie study as more patients retain sufficient muscle control

Outsourcing Pharma

JUNE 5, 2023

Encouraging clinical data has been released by Biovie, a company developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.

An effort to diversify genetic research finds new variant for Parkinson’s disease in African populations

STAT

AUGUST 25, 2023

” Read the rest…

SAEM Clinical Images Series: Neonatal Rash

ALiEM - Pharm Pearls

FEBRUARY 26, 2024

Clinical and therapeutic approach to childhood acne: an update. Copyright Images and cases from the Society of Academic Emergency Medicine (SAEM) Clinical Images Exhibit at the 2023 SAEM Annual Meeting | Copyrighted by SAEM 2023 – all rights reserved. View other cases from this Clinical Image Series on ALiEM.

STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast

STAT

DECEMBER 7, 2023

AbbVie announced plans to purchase Cerevel Therapeutics and its pipeline of experimental neurological and psychiatric medications for $8.7 The framework will detail when the agency might assert this authority, and endorse using drug prices when deciding. billion , STAT writes. The Continue to STAT+ to read the full story…

Drug Pricing

SAEM Clinical Images Series: Workout Gone Wrong

ALiEM - Pharm Pearls

MARCH 15, 2024

Neurologic : Alert and oriented x3 Laboratory Data Non-contributory Case Question: Which part of the eye is affected? View other cases from this Clinical Image Series on ALiEM. Decreased visual field on the right when compared to the left. Left eye is atraumatic in appearance.

Preclinical program with potential for disease modifying therapeutic

Outsourcing Pharma

JANUARY 13, 2023

A license agreement from UCB to Pheno Therapeutics will enable the acceleration of a promising new drug tackling neurological diseases towards clinical development.

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

JULY 26, 2022

Major symptoms of the disease are neurological and developmental disorders, as well as hepatosplenomegaly, jaundice, cholestasis, bleeding disorders and, eventually, dysphagia and even respiratory failure in adults.

Compounding

Compounding Labelling

7 Things You Need to Know Before Taking the Child Neurology Certification Exam

Board Vitals - Pharmacist

AUGUST 26, 2022

The American Board of Psychiatry and Neurology (ABPN) Certification Exam in Child Neurology is a board examination that tests a candidate’s knowledge of the fundamentals of child neurology. The exam is held once a year, and is required to become board certified in Child Neurology. The exam consists of 400 questions.

Communication

Top Resources to Pass the Neurology Boards

Board Vitals - Pharmacist

MAY 13, 2023

Preparing for the neurology board exam requires a comprehensive and strategic study approach. To ensure success, it is vital to utilize high-quality resources that cover the breadth and depth of neurology topics. These platforms offer a vast collection of multiple-choice questions that cover various neurology topics.

STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud

STAT

DECEMBER 22, 2023

For Bristol, the deal represents a re-entry into the market for drugs to treat psychiatric and neurological diseases. Drugmakers that normally try to sell drugs as soon as possible are suspending clinical trials and shifting timelines. … Bristol Myers Squibb agreed to buy Karuna Therapeutics for $14 billion , STAT writes.

Sudo raises $116m to advance TYK2 programmes

Pharmaceutical Technology

DECEMBER 21, 2023

Sudo plans to advance two TYK2 candidates into clinical testing next year for the treatment of autoimmune and neurologic conditions.

STAT+: Pharmalittle: Pfizer scaling back early-stage research into rare diseases; BioNTech and U.K. partner on cancer trials

STAT

JANUARY 6, 2023

The company said it would “externalize” most of its early-stage rare disease programs in neurology and cardiology, and gene therapy programs not yet in clinical trials. Among the assets on the chopping block is a gene therapy manufacturing facility in Durham, N.C.,

Boehringer collaboration could advance first-in-class schizophrenia treatments

European Pharmaceutical Review

MARCH 14, 2024

Boehringer Ingelheim highlighted that GPR52 is a potential emerging therapeutic target for multiple neurological and neuropsychiatric disorders. HTL0048149 began first-in-human clinical trials in 2023, according to an announcement by Sosei in July 2023. Sosei Heptares will receive an upfront payment of €25 million.

SAEM Clinical Images Series: Seeing Double

ALiEM - Pharm Pearls

MARCH 22, 2024

She initially presented to urgent care with a chief complaint of chest heaviness and concern that her blood pressure was too high, but was sent to the emergency department for further cardiac and neurological evaluation after her urgent care provider noticed abnormal eye movement. View other cases from this Clinical Image Series on ALiEM.

Siemens Healthineers, IISc launch laboratory for AI in precision medicine

Express Pharma

JANUARY 24, 2024

The CDS collaborative laboratory will develop open-source AI-based tools to precisely automate the segmentation of pathological findings in neuroimaging data, with a focus on accurately diagnosing neurological diseases and analysing their clinical impact at a population level.

Integrative neuro-oncology for brain tumor patients

World Pharma News

APRIL 26, 2023

Sengupta, associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist,

Neurology’s Growing Need for Disposable Technologies

Pharma Mirror

JANUARY 10, 2021

Several studies have recently shown that the development of neurological conditions and symptoms are prevalent in COVID patients. Neurologic manifestations, including headaches, myalgias, dizziness, and encephalopathy, occur in most hospitalized COVID-19 patients.

Hospitals

STAT+: Pharmalittle: FDA approves a medicine to combat ALS; Medicare drug-price talks are poised to become a legal battle

STAT

OCTOBER 1, 2022

The medicine, called Relyvrio, is not a cure but proved to moderately slow the progression of the neurological disease, which causes weakened muscles, paralysis, and death.

Drug Pricing

SAEM Clinical Images Series: A Man with Blurry Vision

ALiEM - Pharm Pearls

AUGUST 18, 2023

No other neurologic deficits were observed. Copyright Images and cases from the Society of Academic Emergency Medicine (SAEM) Clinical Images Exhibit at the 2021 SAEM Annual Meeting | Copyrighted by SAEM 2021 – all rights reserved. View other cases from this Clinical Image Series on ALiEM.

Diabetes

Diabetes Communication

Solving the “information challenge” of rare disease diagnosis

pharmaphorum

MARCH 22, 2021

We take a look at efforts from charities, the government and digital innovators to boost awareness of rare conditions among GPs and make the clinical pathway smoother for patients. This figure comes from a new report by the Neurological Alliance , which is calling for better treatment and care for these 150,000 people.

Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations

World Pharma News

JUNE 28, 2023

The company will present a deep dive on the innovation strategy in its four therapeutic core areas Oncology, Cardiovascular Diseases, Neurology & Rare Diseases and Immunology.

SAEM Clinical Images Series: Only a Flesh Wound

ALiEM - Pharm Pearls

SEPTEMBER 29, 2023

Case Question: In this stable patient without apparent vascular injury on CTA, what neurologic findings might prompt angiography to rule-out violation of the carotid sheath? CTA is likely to be adequate in most cases of penetrating trauma, but a role may still exist for angiography in the presence of compelling clinical findings.

BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for Primary Photoreceptor Diseases

LifeProNow

FEBRUARY 1, 2024

Our collaboration with the FUJIFILM Cellular Dynamics and Opsis Therapeutics team has allowed us to execute important IND-enabling activities, and we are excited to advance OpCT-001 toward the clinic, with an IND filing planned for this year.”

Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI

World Pharma News

MAY 22, 2023

Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that the company has nominated a potentially best-in-class preclinical candidate targeting ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia (HPP).

Immunity

Immunity Immunization

First RNA CAR-T therapy autoimmunity trial shows potential

European Pharmaceutical Review

JUNE 23, 2023

Study data from a major trial has demonstrated RNA CAR-T (rCAR-T) therapy Descartes-08 facilitated significant and long-lasting clinical improvement in generalised myasthenia gravis (gMG). This is the first clinical trial using rCAR-T to treat autoimmunity. Data from the study was published in The Lancet Neurology.

Chemotherapy

SAEM Clinical Images Series: Incidental Finding on Bedside Echo

ALiEM - Pharm Pearls

MARCH 6, 2023

Distal embolic events can cause neurologic deficit, visceral ischemia, STEMI, and limb ischemia amongst other critical presentatations. Copyright Images and cases from the Society of Academic Emergency Medicine (SAEM) Clinical Images Exhibit at the 2021 SAEM Annual Meeting | Copyrighted by SAEM 2021 – all rights reserved.

Hospitals

Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

Pharmafile

SEPTEMBER 12, 2023

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound NBI-1117570 in healthy adult patients.

Compounding

Startup Neuroglee raises $10m for virtual neurology clinics

The future of clinical research in neurology must be driven by community voices

Trending Sources

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT+: Biotech launches with $82 million for Parkinson’s cell therapy

STAT+: Taysha Gene Therapies’ plan to tackle rare diseases is crumbling

STAT+: After four patients died of gene therapy, Astellas sees possible explanation — and a way forward

STAT+: FDA approves first treatment for Rett syndrome, a genetic neurological disease

Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say

SAEM Clinical Images Series: Intracranial Abnormality

BMS Receives EC Approval for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

STAT+: PTC Therapeutics’s PKU drug succeeds in trial, but bigger hurdles for company are ahead

STAT+: Roche shortens delivery time for multiple sclerosis drug from hours to minutes in trial

Breaking Down the 2024 PRITE Blueprint

AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease

Contineum, a startup born from a Roche buyout, files for IPO

PharmaKure partners with Malaysian university in a bid to predict neurological diseases

STAT+: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn

Encouraging results for Parkinson's Disease drug in Biovie study as more patients retain sufficient muscle control

An effort to diversify genetic research finds new variant for Parkinson’s disease in African populations

SAEM Clinical Images Series: Neonatal Rash

STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast

SAEM Clinical Images Series: Workout Gone Wrong

Preclinical program with potential for disease modifying therapeutic

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

7 Things You Need to Know Before Taking the Child Neurology Certification Exam

Top Resources to Pass the Neurology Boards

STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud

Sudo raises $116m to advance TYK2 programmes

STAT+: Pharmalittle: Pfizer scaling back early-stage research into rare diseases; BioNTech and U.K. partner on cancer trials

Boehringer collaboration could advance first-in-class schizophrenia treatments

SAEM Clinical Images Series: Seeing Double

Siemens Healthineers, IISc launch laboratory for AI in precision medicine

Integrative neuro-oncology for brain tumor patients

Neurology’s Growing Need for Disposable Technologies

STAT+: Pharmalittle: FDA approves a medicine to combat ALS; Medicare drug-price talks are poised to become a legal battle

SAEM Clinical Images Series: A Man with Blurry Vision

Solving the “information challenge” of rare disease diagnosis

Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations

SAEM Clinical Images Series: Only a Flesh Wound

BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for Primary Photoreceptor Diseases

Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI

First RNA CAR-T therapy autoimmunity trial shows potential

SAEM Clinical Images Series: Incidental Finding on Bedside Echo

Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

Stay Connected